Alpha-9 Oncology

📍 Boston, United States🗓 Founded 2018👥 56 employees💰 Last funded Oct 2024
Biotechnology Research🌐 a9oncology.com
Website LinkedIn
Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.
2
Total investors
0
Early stage
0
Mid stage
2
Late stage
2018
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Canada
1
United States
1
Frequently asked questions
Who invested in Alpha-9 Oncology?
Alpha-9 Oncology has 2 investors on record on gritt.io and 2 late-stage investors.
When did Alpha-9 Oncology last raise funding?
The most recent investment in Alpha-9 Oncology recorded on gritt.io was in October 2024.
When was Alpha-9 Oncology founded?
Alpha-9 Oncology was founded in 2018.
What industry is Alpha-9 Oncology in?
Alpha-9 Oncology operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Alpha-9 Oncology based?
Alpha-9 Oncology is headquartered in Boston, United States.